Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Manageable toxicity seen with brivanib alaninate plus cetuximab and irinotecan in colorectal cancer

Nov. 3, 2010

Spectrum Pharma submits additional data to FDA for Fusilev

Nov. 2, 2010

Cellceutix completes final toxicity study of Kevetrin

Nov. 2, 2010

Effects of denosumab reported in patients with prostate cancer and bone metastases

Nov. 2, 2010

FDA approves Sprycel for treatment of newly diagnosed Ph+ CML in chronic phase

Oct. 29, 2010

Astellas applies for Japanese marketing approval for degarelix for prostate cancer

Oct. 29, 2010

Combination of WX-671 and gemcitabine shows promise in phase II trial in pancreatic cancer

Oct. 29, 2010

Celator Pharma completes enrollment in phase II CPX-351 trial in AML

Oct. 28, 2010

Initial phase II results of resminostat in Hodgkin's lymphoma demonstrate favorable safety

Oct. 28, 2010

Treakisym approved in Japan for non-Hodgkin's and mantle cell lymphoma

Oct. 28, 2010

Popular Stories

Today's news in brief
BioWorld
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...